AR024558A1 - COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME - Google Patents
COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAMEInfo
- Publication number
- AR024558A1 AR024558A1 ARP000102690A ARP000102690A AR024558A1 AR 024558 A1 AR024558 A1 AR 024558A1 AR P000102690 A ARP000102690 A AR P000102690A AR P000102690 A ARP000102690 A AR P000102690A AR 024558 A1 AR024558 A1 AR 024558A1
- Authority
- AR
- Argentina
- Prior art keywords
- processes
- compositions
- produce
- same
- beta peptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
- 238000011146 sterile filtration Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se refiere a procesos para preparar composiciones que comprenden al péptido A beta solubilizado o a suspensiones del péptido A beta ajustando el pH losuficiente como para lograr la solubilizacion, y la filtracion estéril de las mismas, a métodos paratratar de prevenir la enfermedad de Alzheimer con lascomposiciones obtenidas y a procesos para producir las mismas.It refers to processes for preparing compositions comprising the solubilized beta A peptide or suspensions of the beta A peptide by adjusting the pH sufficient to achieve solubilization, and sterile filtration thereof, to methods to try to prevent Alzheimer's disease with the compositions obtained and processes to produce them.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13704799P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024558A1 true AR024558A1 (en) | 2002-10-16 |
Family
ID=22475602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102690A AR024558A1 (en) | 1999-06-01 | 2000-05-31 | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1181040A1 (en) |
| JP (1) | JP2003519620A (en) |
| KR (1) | KR20020016813A (en) |
| CN (1) | CN1353615A (en) |
| AR (1) | AR024558A1 (en) |
| AU (1) | AU5726100A (en) |
| BG (1) | BG106249A (en) |
| BR (1) | BR0011251A (en) |
| CA (1) | CA2374897A1 (en) |
| CZ (1) | CZ20014150A3 (en) |
| EE (1) | EE200100649A (en) |
| HK (1) | HK1045938A1 (en) |
| HR (1) | HRP20010901A2 (en) |
| IL (1) | IL146575A0 (en) |
| IS (1) | IS6182A (en) |
| MX (1) | MXPA01012355A (en) |
| NO (1) | NO20015859L (en) |
| NZ (1) | NZ515744A (en) |
| PE (1) | PE20010212A1 (en) |
| PL (1) | PL352575A1 (en) |
| RU (1) | RU2001135800A (en) |
| SK (1) | SK17012001A3 (en) |
| TR (1) | TR200103476T2 (en) |
| WO (1) | WO2000072870A1 (en) |
| ZA (1) | ZA200109704B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| JP5362164B2 (en) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | Prevention and treatment of Alzheimer's disease |
| AU1225702A (en) * | 2000-09-19 | 2002-04-02 | Evotec Neurosciences Gmbh | Methods and compounds for treating brain amyloidosis |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
| TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| TW200636066A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
| WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| CN101506236B (en) | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | Monoclonal antibody against amyloid beta protein and use thereof |
| RU2442793C2 (en) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES |
| PL2004688T5 (en) | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Improved antibodies to protofibrils and their uses |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| ES2498040T3 (en) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases with humanized anti-beta antibodies |
| JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| CN103298833B (en) | 2010-08-14 | 2015-12-16 | Abbvie公司 | beta amyloid binding protein |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| JO3537B1 (en) | 2014-07-10 | 2020-07-05 | Bioarctic Neuroscience Ab | Enhanced amyloid beta-peptide AB primary fibrillary antibodies |
| EP3400022A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| NZ743487A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
| SMT202200466T1 (en) | 2016-01-08 | 2023-01-13 | Ascendis Pharma Growth Disorders As | Cnp prodrugs with carrier attachment at the ring moiety |
| US12377133B2 (en) | 2019-02-11 | 2025-08-05 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of CNP conjugates |
| CN114957438B (en) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | Human Aβ1-42 antigenic determinant polypeptide for detecting Alzheimer's disease and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2081482C (en) * | 1990-04-27 | 2000-11-21 | Ellis L. Kline | Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 AR ARP000102690A patent/AR024558A1/en unknown
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/en not_active Application Discontinuation
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/en unknown
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 HK HK02106241.2A patent/HK1045938A1/en unknown
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/en unknown
- 2000-06-01 EE EEP200100649A patent/EE200100649A/en unknown
- 2000-06-01 IL IL14657500A patent/IL146575A0/en unknown
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/en not_active Application Discontinuation
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Ceased
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/en not_active Withdrawn
- 2000-06-01 CN CN00808374A patent/CN1353615A/en active Pending
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/en not_active Withdrawn
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 HR HR20010901A patent/HRP20010901A2/en not_active Application Discontinuation
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/en unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/en unknown
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/en unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/en not_active Application Discontinuation
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/en unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/en not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL352575A1 (en) | 2003-08-25 |
| EE200100649A (en) | 2003-02-17 |
| ZA200109704B (en) | 2003-02-26 |
| BR0011251A (en) | 2002-03-05 |
| NO20015859L (en) | 2002-02-01 |
| SK17012001A3 (en) | 2002-06-04 |
| PE20010212A1 (en) | 2001-02-22 |
| RU2001135800A (en) | 2003-08-20 |
| EP1181040A1 (en) | 2002-02-27 |
| IS6182A (en) | 2001-11-29 |
| IL146575A0 (en) | 2002-07-25 |
| HRP20010901A2 (en) | 2003-04-30 |
| JP2003519620A (en) | 2003-06-24 |
| KR20020016813A (en) | 2002-03-06 |
| CZ20014150A3 (en) | 2002-05-15 |
| NO20015859D0 (en) | 2001-11-30 |
| MXPA01012355A (en) | 2003-06-24 |
| WO2000072870A1 (en) | 2000-12-07 |
| HK1045938A1 (en) | 2002-12-20 |
| CN1353615A (en) | 2002-06-12 |
| AU5726100A (en) | 2000-12-18 |
| TR200103476T2 (en) | 2002-04-22 |
| NZ515744A (en) | 2004-04-30 |
| BG106249A (en) | 2002-08-30 |
| CA2374897A1 (en) | 2000-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024558A1 (en) | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME | |
| DOP2002000429A (en) | IMIDAZOTRIAZINAS | |
| HN1999000124A (en) | SUBSTITUTED PYRAZOLE DERIVATIVES. | |
| EA200200249A1 (en) | DERIVATIVES 3 (5) -UREIDOPYRAZOL, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS ANTI-TUMOR AGENTS | |
| BRPI0409611A (en) | piperazine derivatives and their use for the treatment of neurological and psychiatric disorders | |
| UY28011A1 (en) | TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| PT1200105E (en) | FACTOR VIII MODIFIED | |
| BR0017026A (en) | Lipeptides as antibacterial agents | |
| DE60037139D1 (en) | POLY-HYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND ALPHA-SYNUCLEIN FIBRIL DISEASES | |
| ES2191511A1 (en) | Erythropoietin derivatives | |
| GT199900067A (en) | NEW 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURTIC DEDERMATOSIS. | |
| ATE249214T1 (en) | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGUES | |
| BRPI0407662A (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
| DE60318839D1 (en) | 2,6-CHINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VLA-4 RELATED DISEASES | |
| DE60024415D1 (en) | THE GLYCIN BETAIN FOR ITS ANTITHROMBOTIC USE | |
| MX9305248A (en) | DIARILPIPERAZINOACETAMIDA COMPOUNDS. | |
| DE60015508D1 (en) | C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOG | |
| CY1110644T1 (en) | 5,6,7-Trihydroxyheptanoic acid and its analogues for the treatment of ophthalmic diseases related to hypercapillary and angiogenic diseases | |
| ATE234636T1 (en) | CONJUGATE COMPRISING AN ACTIVE INGREDIENT, A POLYPEPTIDE AND A POLYETHER | |
| ATE283256T1 (en) | C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOGUE | |
| EA200100700A1 (en) | GENES AND PROTEINS AND THEIR APPLICATION | |
| UY27451A1 (en) | 2,5-DIAMIDOINDOLES REPLACED AND ITS USE | |
| ES2185837T3 (en) | USE OF THEOPHYLIN DERIVATIVES FOR THE TREATMENT AND PROFILAXIS OF SHOCK DISEASES, NEW XANTINE COMPOUNDS AND PROCEDURES FOR PRODUCTION. | |
| BR9807312A (en) | (4-Piperidinyl) -1h-2-benzopyran derivatives useful as antipsychotic agents | |
| ECSP003504A (en) | COMPOSITIONS OF PEPTIDE A - BETA AND PROCESSES TO PRODUCE THE SAME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |